BMS-582949
- Generic Name
- BMS-582949
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26N6O2
- CAS Number
- 623152-17-0
- Unique Ingredient Identifier
- CR743OME9E
- Background
BMS-582949 has been investigated for the treatment of Psoriasis.
- Associated Conditions
- -
- Associated Therapies
- -
PoC in Rheumatoid Arthritis With Methotrexate
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 121
- Registration Number
- NCT00605735
- Locations
- ๐บ๐ธ
G. Timothy Kelly, Md, Las Vegas, Nevada, United States
๐จ๐ณLocal Institution, Taoyuan, Taiwan
๐บ๐ธThe Arthritis Group, Philadelphia, Pennsylvania, United States
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 72
- Registration Number
- NCT00570752
- Locations
- ๐บ๐ธ
Florida Cardiovascular Institute, Tampa, Florida, United States
๐บ๐ธTroy Internal Medince Pc/Research, Troy, Michigan, United States
๐บ๐ธBaylor College Of Medicine, Houston, Texas, United States
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 99
- Registration Number
- NCT00399906
- Locations
- ๐ฒ๐ฝ
Local Institution, Monterrey, Nuevo Leon, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2024. All Rights Reserved by MedPath